Browse Articles

Discover research articles across all indexed journals

How China created AI model DeepSeek and shocked the world

Nature Gemma Conroy, Smriti Mallapaty Feb 13, 2025 DOI: 10.1038/d41586-025-00259-0

Colin Renfrew obituary: archaeologist who shifted thinking on how societies evolve

Nature Cyprian Broodbank Feb 13, 2025 DOI: 10.1038/d41586-025-00220-1

C-terminal amides mark proteins for degradation via SCF–FBXO31

Nature Matthias F. Muhar, Jakob Farnung, Martina Cernakova et al. Feb 13, 2025 DOI: 10.1038/s41586-024-08475-w

Abstract During normal cellular homeostasis, unfolded and mislocalized proteins are recognized and removed, preventing the build-up of toxic byproducts 1 . When protein homeostasis is perturbed during ageing, neurodegeneration or cellular stress, proteins can accumulate several forms of chemical damage through reactive metabolites 2,3 . Such modifications have been proposed to trigger the selective removal of chemically marked proteins 3–6 ; however, identifying modifications that are sufficient to induce protein degradation has remained challenging. Here, using a semi-synthetic chemical biology approach coupled to cellular assays, we found that C-terminal amide-bearing proteins (CTAPs) are rapidly cleared from human cells. A CRISPR screen identified FBXO31 as a reader of C-terminal amides. FBXO31 is a substrate receptor for the SKP1–CUL1–F-box protein (SCF) ubiquitin ligase SCF–FBXO31, which ubiquitylates CTAPs for subsequent proteasomal degradation. A conserved binding pocket enables FBXO31 to bind to almost any C-terminal peptide bearing an amide while retaining exquisite selectivity over non-modified clients. This mechanism facilitates binding and turnover of endogenous CTAPs that are formed after oxidative stress. A dominant human mutation found in neurodevelopmental disorders reverses CTAP recognition, such that non-amidated neosubstrates are now degraded and FBXO31 becomes markedly toxic. We propose that CTAPs may represent the vanguard of a largely unexplored class of modified amino acid degrons that could provide a general strategy for selective yet broad surveillance of chemically damaged proteins.

Signs of damage that drive protein degradation

Nature Alfred Freeberg, Michael Rapé Feb 13, 2025 DOI: 10.1038/d41586-025-00082-7

NEJM at AHA — Routine Spironolactone in Acute Myocardial Infarction

New England Journal of Medicine Eric J. Rubin, Jane Leopold, Stephen Morrissey Feb 13, 2025 DOI: 10.1056/nejme2414472

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12C

New England Journal of Medicine Feb 13, 2025 DOI: 10.1056/nejmx240006

Maternal Anti-PF4 Antibodies as Cause of Neonatal Stroke

New England Journal of Medicine Silke Häusler, Linda Schönborn, Johann Gradl et al. Feb 13, 2025 DOI: 10.1056/nejmc2413301

Microsatellite-Instability–High Metastatic Colorectal Cancer

New England Journal of Medicine Feb 13, 2025 DOI: 10.1056/nejmc2416383

Bat genomes illuminate adaptations to viral tolerance and disease resistance

Nature Ariadna E. Morales, Yue Dong, Thomas Brown et al. Feb 13, 2025 DOI: 10.1038/s41586-024-08471-0

Transcatheter Repair versus Mitral-Valve Surgery for Secondary Mitral Regurgitation

New England Journal of Medicine Feb 13, 2025 DOI: 10.1056/nejmc2416118

Colchicine in Acute Myocardial Infarction

New England Journal of Medicine Sanjit S. Jolly, Marc-André d’Entremont, Shun Fu Lee et al. Feb 13, 2025 DOI: 10.1056/nejmoa2405922

Routine Spironolactone in Acute Myocardial Infarction

New England Journal of Medicine Sanjit S. Jolly, Marc-André d’Entremont, Bertram Pitt et al. Feb 13, 2025 DOI: 10.1056/nejmoa2405923

NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors

New England Journal of Medicine Eric J. Rubin, Oladapo O. Yeku, Stephen Morrissey Feb 13, 2025 DOI: 10.1056/nejme2411486

Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation

New England Journal of Medicine Feb 13, 2025 DOI: 10.1056/nejmc2416116

Tumoral Melanosis

New England Journal of Medicine Deshan F. Sebaratnam, James P. Pham Feb 13, 2025 DOI: 10.1056/nejmicm2413467

My Mother’s Choices

New England Journal of Medicine Hannah Kirsch Feb 13, 2025 DOI: 10.1056/nejmp2410639

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

New England Journal of Medicine Jennifer A. Chan, Susan Geyer, Tyler Zemla et al. Feb 13, 2025 DOI: 10.1056/nejmoa2403991

Tirzepatide for Congenital Generalized Lipodystrophy

New England Journal of Medicine Svetlana Ten, Amrit Bhangoo, Christoph Buettner Feb 13, 2025 DOI: 10.1056/nejmc2413871

Marburg Virus Disease in Rwanda — Centering Both Evidence and Equity

New England Journal of Medicine Cameron T. Nutt Feb 13, 2025 DOI: 10.1056/nejmp2415557

Lung Transplantation

New England Journal of Medicine Feb 13, 2025 DOI: 10.1056/nejmc2416119